BioSpace News Archive

Drug Development

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. announced today that the enrollment and dosing of participants is underway in ODYSSEY, its randomized, Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).

July 17, 2023
·
8 min read
Drug Development

Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder

Tonix Pharmaceuticals Holding Corp. , today announced that the first participant has been enrolled in a Phase 2 investigator-initiated, proof-of-concept study of TNX-1900 (potentiated intranasal oxytocin) for enhancing social safety learning in social anxiety disorder (SAD).

July 17, 2023
·
18 min read
Deals

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 17, 2023

EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

July 17, 2023
·
1 min read
BioMidwest

AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership

AccuStem Sciences, Inc. and EmeritusDX announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem’s product portfolio.

July 17, 2023
·
5 min read
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics, Inc. today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID.

July 17, 2023
·
7 min read
Business

Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer

Atavistik Bio today announced the appointment of Bryan Stuart as Chief Executive Officer (CEO) and a Director on the company’s Board.

July 17, 2023
·
3 min read
Genetown

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and the Ministry of Health representing the Government of the Republic of Botswana announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.

July 17, 2023
·
6 min read
Business

Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress

Lyndra Therapeutics today announced long-time Lyndra executive President and Chief Operations Officer Jessica Ballinger has been appointed President and CEO.

July 17, 2023
·
6 min read
Business

Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

Castle Biosciences, Inc. today announced that it has earned a second consecutive Arizona Top Workplace award from AZ Central, the digital home of The Arizona Republic newspaper.

July 17, 2023
·
3 min read
Business

Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors

Avertix Medical, Inc. announced that Professor Ian Meredith AM, has agreed to join the Company’s Board of Directors following the closing of the Company’s previously announced business combination with BIOS Acquisition Corporation, a special purpose acquisition company.

July 17, 2023
·
12 min read